CPH: Cipher Pharmaceuticals Inc. - Summary | Jitta

Cipher Pharmaceuticals Inc.

CAN:CPH

Price
CA$4.25
Loss Chance
42.5%
6.07JITTA SCORE
54.66%Under Jitta Line
Jitta Ranking
11 / 110
130 / 1,984
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (50)
Recent Business Performance (55)
Financial Strength (91)
Return to Shareholders (57)
Competitive Advantage (51)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
Share RepurchaseEvery Year
CapExVery Low
SG&A to SalesDecreasing
Cash Conversion CycleLess than 30 days
Revenue and EarningRevenue decline from 2017-2022
Operating MarginDeclined
Key Stats
Jitta Score
Jitta Line
6.07
54.66%
2.14
68.42%
2.37
105.64%
Pharmaceuticals
4.12
66.53%
4.12
66.53%
3.07
317.36%
COMPANY DESCRIPTION
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company’s licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.